MASH Market Report 2034: Statistics, Revenue, Patient Pool, EMA, PDMA, FDA Approvals, Clinical Trials, Medication, MOA, ROA and Companies by DelveInsight
MASH Companies are Boehringer Ingelheim, Hepagene, Eli Lilly and Company, Hepion Pharmaceuticals, Ionis Pharmaceuticals, Galectin Therapeutics, Novo Nordisk A/S, Merck & Co., Zealand Pharma, Hanmi Pharmaceutical, Inventiva Pharma, Cirius Therapeutics, HighTide Biopharma, Pfizer, Lipocine, Corcept Therapeutics, Poxel SA, Enyo Pharmaceuticals, Akero Therapeutics, Zydus Therapeutics, 89bio, Viking Therapeutics, Boston Pharmaceuticals, Gilead Sciences, CytoDyn, Sagimet Biosciences, and others.
(Albany, USA) DelveInsight's Metabolic Dysfunction-Associated Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, MASH emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
The MASH market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted MASH market size from 2020 to 2034, segmented by seven major markets. The Report also covers current MASH treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the MASH market.
Key Takeaways from the Metabolic Dysfunction-Associated Steatohepatitis Market Report
The total MASH market size in the 7MM was approximately USD 2,114 million in 2023 and is projected to increase during the forecast period (2024–2034).
In 2023, there were an estimated 42 million prevalent cases of MASH in the 7MM. Out of these, a total of ~15 million cases were diagnosed, and this number is projected to increase by the end of 2034 in the 7MM.
Leading MASH companies such as Inventiva Pharma, Novo Nordisk A/S, Cirius Therapeutics, Akero Therapeutics, 89bio, Boehringer Ingelheim, Zealand Pharma, Galectin Therapeutics, Lipocine, Viking Therapeutics, Eli Lilly and Company, Boston Pharmaceuticals, Pfizer, HighTide Biopharma, CytoDyn, Merck & Co., Hanmi Pharmaceutical, Hepagene (Shanghai), Hepion Pharmaceuticals, Enyo Pharmaceuticals, Gilead Sciences, Poxel SA, Zydus Therapeutics, Sagimet Biosciences, Ionis Pharmaceuticals, Corcept Therapeutics, and others are developing novel MASH drugs that can be available in the MASH market in the coming years.
The promising MASH therapies in the pipeline include Lanifibranor (IVA337), Semaglutide, Azemiglitazone (MSDC-0602K), Efruxifermin (EFX), BIO89-100 (Pegozafermin), Survodutide (BI 456906), GR-MD-02 (Belapectin), LPCN1144, VK2809, Tirzepatide, BOS-580, Ervogastat (PF-06865571) + Clesacostat (PF-05221304), HTD1801, Leronlimab (PRO 140), Efinopegdutide, HPG1860, Rencofilstat (CRV431), EYP001 (Vonafexor), Semaglutide/Cilofexor/Firsocostat, PXL065, Saroglitazar Magnesium, Denifanstat (TVB-2640), ION224, Miricorilant (CORT118335), and others.
In March 2024, Madrigal Pharmaceuticals' groundbreaking product, REZDIFFRA (resmetirom), a once-daily, oral THR-ß agonist, received accelerated endorsement from the US FDA based on results from the Phase III MAESTRO-NASH trial. This approval marks a significant stride in the medical landscape, as REZDIFFRA becomes the inaugural and sole FDA-sanctioned therapy for adults afflicted with non-cirrhotic MASH, accompanied by moderate to advanced liver scarring (fibrosis) corresponding to stages F2–F3 fibrosis.
Discover which therapies are expected to grab the major MASH market share @ Metabolic Dysfunction-Associated Steatohepatitis Market Report
Metabolic Dysfunction-Associated Steatohepatitis Overview
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease that stems from metabolic dysfunction, often linked to obesity, diabetes, and other conditions of metabolic syndrome. MASH is characterized by the accumulation of fat in liver cells, accompanied by inflammation and liver cell injury, which can progress to fibrosis, cirrhosis, or even liver cancer.
The primary drivers of MASH include insulin resistance, obesity, type 2 diabetes, and dyslipidemia. Genetic predisposition and a sedentary lifestyle also play significant roles. Environmental factors, such as a poor diet high in sugars and fats, exacerbate the condition.
MASH is often asymptomatic in its early stages. When MASH symptoms occur, they can include fatigue, vague abdominal discomfort, or pain in the upper right quadrant. In advanced stages, signs of liver dysfunction such as jaundice, swelling of the abdomen or legs, and confusion may arise.
MASH Diagnosis involves a combination of clinical history, physical examination, and diagnostic tests. Blood tests measuring liver enzymes (ALT, AST) often indicate liver inflammation. Imaging techniques like ultrasound, MRI, or FibroScan can identify liver fat and fibrosis. In some cases, a liver biopsy is required to confirm the diagnosis and assess disease severity.
Metabolic Dysfunction-Associated Steatohepatitis Epidemiology Segmentation
The MASH epidemiology section provides insights into the historical and current MASH patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The MASH market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Prevalent Cases of MASH
Diagnosed Prevalent Cases of MASH
Gender-specific Diagnosed Prevalent Cases of MASH
Severity-specific Diagnosed Prevalent Cases of MASH
MASH Treatment Market
The approval of REZDIFFRA (resmetirom) in March 2024 represents a pivotal achievement in medical innovation, transforming the treatment landscape for MASH disease. This groundbreaking therapy addresses the root causes of MASH, offering renewed hope to patients grappling with this challenging condition. Clinical trials have shown impressive results, with REZDIFFRA effectively reducing symptoms like inflammation and fibrosis, enhancing liver function, and improving patients' quality of life. By providing healthcare professionals with a robust treatment option, this approval addresses a critical unmet need and has the potential to significantly alleviate the complications linked to advanced liver disease.
The prevalence of MASLD is strongly linked to type 2 diabetes mellitus and obesity, particularly in individuals with a higher body mass index. However, MASLD occurrence is reduced in T2DM patients receiving treatments such as sodium-glucose cotransporter-2 (SGLT2) inhibitors, GLP-1 receptor agonists, and insulin. Vitamin E, with its antioxidant properties, is regarded as a first-line pharmacological option for managing MASH, especially when dietary and lifestyle interventions are insufficient.
Metabolic Dysfunction-Associated Steatohepatitis Pipeline Therapies and Key Companies
Lanifibranor (IVA337): Inventiva Pharma
Semaglutide: Novo Nordisk A/S
Azemiglitazone (MSDC-0602K): Cirius Therapeutics
Efruxifermin (EFX): Akero Therapeutics
BIO89-100 (Pegozafermin): 89bio
Survodutide (BI 456906): Boehringer Ingelheim/Zealand Pharma
GR-MD-02 (Belapectin): Galectin Therapeutics
LPCN1144: Lipocine
VK2809: Viking Therapeutics
Tirzepatide: Eli Lilly and Company
BOS-580: Boston Pharmaceuticals
Ervogastat (PF-06865571) + Clesacostat (PF-05221304): Pfizer
HTD1801: HighTide Biopharma
Leronlimab (PRO 140): CytoDyn
Efinopegdutide: Merck & Co./Hanmi Pharmaceutical
HPG1860: Hepagene (Shanghai)
Rencofilstat (CRV431): Hepion Pharmaceuticals
EYP001 (Vonafexor): Enyo Pharmaceuticals
Semaglutide/ Cilofexor/ Firsocostat: Gilead Sciences
PXL065: Poxel SA
Saroglitazar Magnesium: Zydus Therapeutics
Denifanstat (TVB-2640): Sagimet Biosciences
ION224: Ionis Pharmaceuticals
Miricorilant (CORT118335): Corcept Therapeutics
Discover more about MASH drugs in development @ Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials and Advancements
MASH Market Dynamics
The MASH market dynamics are expected to change in the coming years. Growing research activities and multiple clinical trials for MASH, driven by the rapid surge in its prevalence due to rising obesity and type 2 diabetes rates, highlight an active drug development pipeline and an expanding market size. The large pool of patients and lucrative growth opportunities present attractive prospects for key players, further supported by ongoing preclinical studies aimed at advancing imaging techniques for MASH diagnosis, potentially eliminating the need for invasive biopsy-based histopathological confirmation.
Furthermore, potential therapies are being investigated for the treatment of MASH, and it is safe to predict that the treatment space will significantly impact the MASH market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the MASH market in the 7MM.
However, several factors may impede the growth of the MASH market. Lack of awareness and negligence in the early stages of MASH by physicians often lead to disease progression, culminating in irreversible damage where liver transplantation becomes the only viable option. Diagnosing advanced MASH typically requires procedures like liver biopsy, which are costly, invasive, and risky. Regulatory challenges also pose hurdles, as the FDA mandates achieving one MASH endpoint for approval, while the EMA's draft guidance requires efficacy in both endpoints, potentially delaying first-mover approvals in major European markets. Additionally, access to expensive MASH treatments may be limited in certain regions, further hindering patient adoption.
Moreover, MASH treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, MASH market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact MASH market growth.
Download the report to understand which factors are driving MASH drugs and therapies in pipeline @ Metabolic Dysfunction-Associated Steatohepatitis Treatment Market
Scope of the Metabolic Dysfunction-Associated Steatohepatitis Market Report
Study Period: 2020–2034
Coverage: 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
Metabolic Dysfunction-Associated Steatohepatitis CAGR: 17.9 %
Metabolic Dysfunction-Associated Steatohepatitis Market Size in 2023: USD 2.1 Billion
Key Metabolic Dysfunction-Associated Steatohepatitis Companies: Hepion Pharmaceuticals (NASDAQ: HEPG), Ionis Pharmaceuticals (NASDAQ: IONS), Galectin Therapeutics (NASDAQ: GALT), Novo Nordisk A/S (NYSE: NVO), Cirius Therapeutics (Private), HighTide Biopharma (TSX-V: HBT), Boehringer Ingelheim (Private), Hepagene (Private), Eli Lilly and Company (NYSE: LLY), Pfizer (NYSE: PFE), Lipocine (NASDAQ: LPCN), Corcept Therapeutics (NASDAQ: CORT), Poxel SA (EPA: POXEL), Enyo Pharmaceuticals (Private), Akero Therapeutics (NASDAQ: AKRO), Zydus Therapeutics (NSE: ZYDUSLIFE), 89bio (NASDAQ: ETNB), Viking Therapeutics (NASDAQ: VKTX), Boston Pharmaceuticals (Private), Gilead Sciences (NASDAQ: GILD), Merck & Co. (NYSE: MRK), Zealand Pharma (CPH: ZEAL), Hanmi Pharmaceutical (KRX: 128940), Inventiva Pharma (EPA: IVA), CytoDyn (OTCQB: CYDY), Sagimet Biosciences (NASDAQ: SGMT).
Key Pipeline Metabolic Dysfunction-Associated Steatohepatitis Therapies: Lanifibranor (IVA337), Semaglutide, Azemiglitazone (MSDC-0602K), Efruxifermin (EFX), BIO89-100 (Pegozafermin), Survodutide (BI 456906), GR-MD-02 (Belapectin), LPCN1144, VK2809, Tirzepatide, BOS-580, Ervogastat (PF-06865571) + Clesacostat (PF-05221304), HTD1801, Leronlimab (PRO 140), Efinopegdutide, HPG1860, Rencofilstat (CRV431), EYP001 (Vonafexor), Semaglutide/Cilofexor/Firsocostat, PXL065, Saroglitazar Magnesium, Denifanstat (TVB-2640), ION224, Miricorilant (CORT118335), and others
Therapeutic Assessment: Metabolic Dysfunction-Associated Steatohepatitis current marketed and emerging therapies
Metabolic Dysfunction-Associated Steatohepatitis Market Dynamics: Key Market Forecast Assumptions of Emerging Metabolic Dysfunction-Associated Steatohepatitis Drugs and Market Outlook
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Download the report to understand which factors are driving MASH market trends @ Metabolic Dysfunction-Associated Steatohepatitis Market Trends
Table of Contents
1. Key Insights
2. Report Introduction
3. Country-wise MASH Market Overview at a Glance
4. MASH Market Overview by Therapeutic Class
5. Methodology of MASH Epidemiology and Market
6. Executive Summary
7. Key Events
8. Disease Background and Overview
9. MASH Epidemiology and Patient Population
10. MASH Patient Journey
11. Marketed MASH Drugs
12. Emerging MASH Drugs
13. MASH Market Analysis
14. Key Opinion Leaders' Views
15. SWOT Analysis
16. Unmet needs
17. Market Access and Reimbursement
18. Appendix
19. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/ats-conference-coverage
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
2 hours ago
- CTV News
Deep belly fat triggers inflammation. Here's how to reduce it
You can extend your health span by keeping visceral fat in check, doctors say.(ozgurcankaya/iStockphoto/Getty Images via CNN Newsource) Hiding deep inside the body, a dangerous type of fat wraps itself around vital organs such as the kidneys, liver and heart — triggering inflammation that can lead to insulin resistance and chronic diseases which cut life short. Called visceral fat, it can make bellies expand — but not for everyone. Even people who are thin can carry too much visceral fat around their organs, a phenomenon known as 'skinny fat.' 'Visceral fat is a marker for everything — insulin resistance, elevated cardiovascular risk, fatty liver and Type 2 diabetes — all very bad outcomes that limit a long and healthy life,' said Dr. Andrew Freeman, director of cardiovascular prevention and wellness at National Jewish Health in Denver. Excessive deep belly fat is even linked to long-term cognitive health, said preventive neurologist Dr. Kellyann Niotis, who researches Alzheimer's disease and Parkinson's disease risk reduction at the Institute for Neurodegenerative Diseases in Boca Raton, Florida. 'Visceral fat is metabolically unhealthy and secretes a lot of inflammatory chemicals that can cause brain atrophy and impact cognition,' Niotis told CNN in a prior interview. As the size of a person's belly grows, studies show the memory center of the brain shrinks and hallmark signs of Alzheimer's disease can appear — namely beta-amyloid plaques and tau tangles. This accelerated march toward dementia can begin as early as the 40s and 50s, well before any cognitive decline is apparent, according to researchers. How do you know if you have visceral fat? If visceral fat is about 10% of your body's total fat mass, that's normal and healthy, according to the Cleveland Clinic. So how do you know if that tummy starting to obscure your view of your feet is out of control? One way to tell is to measure your waistline. Non-pregnant women with a waist size greater than 35 inches (88.9 centimetres) and men with a waist greater than 40 inches (101.6 centimetres) are at higher risk from visceral fat, according to the U.S. Centers for Disease Control and Prevention. You can measure your waistline yourself: Without sucking in your tummy, wrap a tape measure over your waist at the top of your hip bone (typically across the belly button). Exhale normally and measure, making sure that the tape is parallel to the floor and snug, but not tight, across the skin. (No cheating by sucking in your stomach — this is your health at risk.) Another key sign is lean muscle mass. If you have more body fat than muscle mass, you're more likely to have visceral fat throughout the body, even the muscles, Freeman said. You can measure lean muscle mass with a yearly DEXA scan, a large noninvasive X-ray machine that measures bone density, internal visceral fat and muscle mass. There are also over-the-counter biometric scales that track percentages of body and visceral fat and lean muscle mass. Then there is common sense, Freeman said. Poor exercise and eating habits are a red flag for belly fat, now and in the future. 'Human beings were designed to be fit and strong and active,' he said. 'Eating ultraprocessed foods and not doing cardio and strength training are good signs that if you don't have excess now, you may soon — even if you don't look 'fat.'' Key ways to reduce visceral fat Want to make a change? Visceral fat is reversible with lifestyle changes, Freeman said. 'The real holy grail, the elixir of youth, the key to staying young and aging gracefully is to remain strong and fit,' he said. Always check with your doctor before beginning any new exercise program. Then start with cardio to get the heart pumping, Freeman said. A good method is to briskly walk for at least 30 minutes a day —'but when I say briskly, I mean fast enough to lose your breath and not be able to hold a conversation. Keep that up for a half hour at a minimum.' The critical next step is to add resistance, otherwise known as strength training, he added. 'When I tell people to go walking or biking or swimming or jogging, I usually recommend that they do resistance concurrently,' Freeman said. 'Carry some weights with them, or put on a weighted backpack, put resistance on the bike or bike uphill, and put fins on their hands when they swim so that there's resistance in the water. Do whatever they need to try to combine the cardio with strength training.' Some of the most effective resistance exercises for building lean muscle and losing fat require multiple joints in the body to work together, according to the nonprofit American Council on Exercise. Dead lifts, lunges, planks, presses, pull-ups and push-ups require many muscles that elevate oxygen use and the release of hormones such as adrenaline that increase blood flow to muscles and boost overall heart rate — both key goals. As you build lean muscle mass, try to add weight, increase sets and repetition, and reduce the breaks you take between exercises. If you're unsure how to do that without injuring yourself, seek out the advice of a physical trainer, the council suggests. 'If you're doing all the right things and you're not building muscle mass, talk to your doctor to rule out issues such as low testosterone that may be hindering your progress,' Dr. Richard Isaacson, director of research at the Institute for Neurodegenerative Diseases, told CNN previously. Address your diet Plant-based diets are excellent ways to improve nutrition and lose belly fat, experts say. 'Get rid of the standard American diet, filled with all the ultraprocessed foods and added fats, sugars and the like and switch to a predominantly whole foods diet,' Freeman said. The Mediterranean diet — which is more of a lifestyle than a diet — has won top honours since 2019 for its focus on eating fruits, vegetables, grains, olive oil, nuts and seeds, while emphasizing the importance of meals with family and friends and daily exercise. The diet also slashes consumption of sweets and recommends small amounts of dairy and meat, especially red meat. Fish, however, is a staple, especially fatty fish such as sardines. Older people who followed a lower-calorie Mediterranean diet and minimally exercised up to six days a week gained muscle and lost a significant amount of body fat by the end of a year and kept much of it off for three years, according to an October 2023 study. A May 2024 study found the Mediterranean dietary pattern cut the risk of death for women by about 25% for more than 25 years, with reductions in both cancer and cardiovascular mortality. Changing when you eat may also help. Try a pattern of eating called intermittent fasting or time-restricted eating, Freeman said. However, he added, it doesn't work for everyone. 'People who are struggling with weight loss have to get their bodies out of its routine, and that's very hard to do,' Freeman said. 'Some people, not everyone, respond by some degree to time-restricted eating. 'You eat breakfast at 11 o'clock, you eat dinner by five o'clock — so six hours a day you're eating, and 18 hours a day you're not. Combine that with strength and cardio training and change the type of fuel to whole foods. You put all those together, and magic things start to happen.' By Sandee LaMotte, CNN
CTV News
21 hours ago
- CTV News
Many forget the damage done by diseases like whooping cough, measles and rubella. Not these families
Jacque Farnham, 60, left, walks with her mother, Janith, 80, to the Visual Arts Center at the Washington Pavilion in Sioux Falls, S.D., on May 20, 2025. (AP Photo/Shelby Lum) SIOUX FALLS, S.D. — In the time before widespread vaccination, death often came early. Devastating infectious diseases ran rampant in America, killing millions of children and leaving others with lifelong health problems. These illnesses were the main reason why nearly one in five children in 1900 never made it to their fifth birthday. Over the next century, vaccines virtually wiped out long-feared scourges like polio and measles and drastically reduced the toll of many others. Today, however, some preventable, contagious diseases are making a comeback as vaccine hesitancy pushes immunization rates down. And well-established vaccines are facing suspicion even from public officials, with Robert F. Kennedy Jr., a longtime anti-vaccine activist, running the federal health department. 'This concern, this hesitancy, these questions about vaccines are a consequence of the great success of the vaccines – because they eliminated the diseases,' said Dr. William Schaffner, an infectious disease expert at Vanderbilt University Medical Center. 'If you're not familiar with the disease, you don't respect or even fear it. And therefore you don't value the vaccine.' Anti-vaccine activists even portray the shots as a threat, focusing on the rare risk of side effects while ignoring the far larger risks posed by the diseases themselves — and years of real-world data that experts say proves the vaccines are safe. Some Americans know the reality of these preventable diseases all too well. For them, news of measles outbreaks and rising whooping cough cases brings back terrible memories of lives forever changed – and a longing to spare others from similar pain. Getting rubella while pregnant shaped two lives With a mother's practiced, guiding hand, 80-year-old Janith Farnham helped steer her 60-year-old daughter's walker through a Sioux Falls art center. They stopped at a painting of a cow wearing a hat. Janith pointed to the hat, then to her daughter Jacque's Minnesota Twins cap. Jacque did the same. 'That's so funny!' Janith said, leaning in close to say the words in sign language too. Jacque was born with congenital rubella syndrome, which can cause a host of issues including hearing impairment, eye problems, heart defects and intellectual disabilities. There was no vaccine against rubella back then, and Janith contracted the viral illness very early in the pregnancy, when she had up to a 90 per cent chance of giving birth to a baby with the syndrome. Janith recalled knowing 'things weren't right' almost immediately. The baby wouldn't respond to sounds or look at anything but lights. She didn't like to be held close. Her tiny heart sounded like it purred – evidence of a problem that required surgery at four months old. Janith did all she could to help Jacque thrive, sending her to the Colorado School for the Deaf and the Blind and using skills she honed as a special education teacher. She and other parents of children with the syndrome shared insights in a support group. Meanwhile, the condition kept taking its toll. As a young adult, Jacque developed diabetes, glaucoma and autistic behaviors. Eventually, arthritis set in. Today, Jacque lives in an adult residential home a short drive from Janith's place. Above her bed is a net overflowing with stuffed animals. On a headboard shelf are photo books Janith created, filled with memories like birthday parties and trips to Mount Rushmore. Jacque's days typically begin with an insulin shot and breakfast before she heads off to a day program. She gets together with her mom four or five days a week. They often hang out at Janith's townhome, where Jacque has another bedroom decorated with her own artwork and quilts Janith sewed for her. Jacque loves playing with Janith's dog, watching sports on television and looking up things on her iPad. Janith marvels at Jacque's sense of humour, gratefulness, curiosity and affectionate nature despite all she's endured. Jacque is generous with kisses and often signs 'double I love yous' to family, friends and new people she meets. 'When you live through so much pain and so much difficulty and so much challenge, sometimes I think: Well, she doesn't know any different,' Janith said. Given what her family has been through, Janith believes younger people are being selfish if they choose not to get their children the MMR shot against measles, mumps and rubella. 'It's more than frustrating. I mean, I get angry inside,' she said. 'I know what can happen, and I just don't want anybody else to go through this.' Delaying the measles vaccine can be deadly More than half a century has passed, but Patricia Tobin still vividly recalls getting home from work, opening the car door and hearing her mother scream. Inside the house, her little sister Karen lay unconscious on the bathroom floor. It was 1970, and Karen was 6. She'd contracted measles shortly after Easter. While an early vaccine was available, it wasn't required for school in Miami where they lived. Karen's doctor discussed immunizing the first grader, but their mother didn't share his sense of urgency. 'It's not that she was against it,' Tobin said. 'She just thought there was time.' Then came a measles outbreak. Karen – who Tobin described as a 'very endearing, sweet child' who would walk around the house singing – quickly became very sick. The afternoon she collapsed in the bathroom, Tobin, then 19, called the ambulance. Karen never regained consciousness. 'She immediately went into a coma and she died of encephalitis,' said Tobin, who stayed at her bedside in the hospital. 'We never did get to speak to her again.' Today, all states require that children get certain vaccines to attend school. But a growing number of people are making use of exemptions allowed for medical, religious or philosophical reasons. Vanderbilt's Schaffner said fading memories of measles outbreaks were exacerbated by a fraudulent, retracted study claiming a link between the MMR shot and autism. The result? Most states are below the 95 per cent vaccination threshold for kindergartners — the level needed to protect communities against measles outbreaks. 'I'm very upset by how cavalier people are being about the measles,' Tobin said. 'I don't think that they realize how destructive this is.' Polio changed a life twice One of Lora Duguay's earliest memories is lying in a hospital isolation ward with her feverish, paralyzed body packed in ice. She was three years old. 'I could only see my parents through a glass window. They were crying and I was screaming my head off,' said Duguay, 68. 'They told my parents I would never walk or move again.' It was 1959 and Duguay, of Clearwater, Fla., had polio. It mostly preyed on children and was one of the most feared diseases in the U.S., experts say, causing some terrified parents to keep children inside and avoid crowds during epidemics. Given polio's visibility, the vaccine against it was widely and enthusiastically welcomed. But the early vaccine that Duguay got was only about 80 per cent to 90 per cent effective. Not enough people were vaccinated or protected yet to stop the virus from spreading. Duguay initially defied her doctors. After intensive treatment and physical therapy, she walked and even ran – albeit with a limp. She got married, raised a son and worked as a medical transcriptionist. But in her early 40s, she noticed she couldn't walk as far as she used to. A doctor confirmed she was in the early stages of post-polio syndrome, a neuromuscular disorder that worsens over time. One morning, she tried to stand up and couldn't move her left leg. After two weeks in a rehab facility, she started painting to stay busy. Eventually, she joined arts organizations and began showing and selling her work. Art 'gives me a sense of purpose,' she said. These days, she can't hold up her arms long enough to create big oil paintings at an easel. So she pulls her wheelchair up to an electric desk to paint on smaller surfaces like stones and petrified wood. The disease that changed her life twice is no longer a problem in the U.S. So many children get the vaccine — which is far more effective than earlier versions — that it doesn't just protect individuals but it prevents occasional cases that arrive in the U.S. from spreading further. ' Herd immunity ' keeps everyone safe by preventing outbreaks that can sicken the vulnerable. After whooping cough struck, 'she was gone' Every night, Katie Van Tornhout rubs a plaster cast of a tiny foot, a vestige of the daughter she lost to whooping cough at just 37 days old. Callie Grace was born on Christmas Eve 2009 after Van Tornhout and her husband tried five years for a baby. She was six weeks early but healthy. 'She loved to have her feet rubbed,' said the 40-year-old Lakeville, Indiana mom. 'She was this perfect baby.' When Callie turned a month old, she began to cough, prompting a visit to the doctor, who didn't suspect anything serious. By the following night, Callie was doing worse. They went back. In the waiting room, she became blue and limp in Van Tornhout's arms. The medical team whisked her away and beat lightly on her back. She took a deep breath and giggled. Though the giggle was reassuring, the Van Tornhouts went to the ER, where Callie's skin turned blue again. For a while, medical treatment helped. But at one point she started squirming, and medical staff frantically tried to save her. 'Within minutes,' Van Tornhout said, 'she was gone.' Van Tornhout recalled sitting with her husband and their lifeless baby for four hours, 'just talking to her, thinking about what could have been.' Callie's viewing was held on her original due date – the same day the Centers for Disease Control and Prevention called to confirm she had pertussis, or whooping cough. She was too young for the Tdap vaccine against it and was exposed to someone who hadn't gotten their booster shot. Today, next to the cast of Callie's foot is an urn with her ashes and a glass curio cabinet filled with mementos like baby shoes. 'My kids to this day will still look up and say, 'Hey Callie, how are you?'' said Van Tornhout, who has four children and a stepson. 'She's part of all of us every day.' Van Tornhout now advocates for childhood immunization through the nonprofit Vaccinate Your Family. She also shares her story with people she meets, like a pregnant customer who came into the restaurant her family ran saying she didn't want to immunize her baby. She later returned with her vaccinated four-month-old. 'It's up to us as adults to protect our children – like, that's what a parent's job is,' Van Tornhout said. 'I watched my daughter die from something that was preventable … You don't want to walk in my shoes.' The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content. Laura Ungar, The Associated Press
CTV News
2 days ago
- CTV News
How To Choose A Dehumidifier
If your home's air is exceptionally moist during summer and you want an easy, efficient method of drying the air, a dehumidifier is the best way to go. Musty air feels gross on our skin, and high humidity levels can cause issues for people with asthma and other respiratory conditions, especially if it leads to mildew and mould growth in your home. No matter your square footage, desired humidity levels, and budget, there is a perfect dehumidifier out there for you. If you think about all of the features and considerations below, you'll be working with the best dehumidifier in no time. What Is a Dehumidifier? A dehumidifier is a portable appliance that removes excess moisture from the air. While some models work with your air conditioner, most are portable dehumidifiers that you can move around your home as you see fit. They work by using refrigerated coils to rapidly cool air that is sucked into the machine. The cold creates condensation that is collected in a basin at the base of the machine or hosed directly outside, depending on your model. Then, the drier, cooler air is released back into your home. Some humidifiers use speed settings to control the process, while others have something called a humidistat that allows users to set a specific humidity setting, such as 50%, and the machine will automatically maintain that setting. Questions to Ask Yourself Before Buying a Dehumidifier How Large is My Room? Humidifiers are not a one-size-fits-all appliance. Each one has a different square footage rating, meaning they can only cover a room up to a certain size. You'll need to measure your room to obtain the total square feet of the area before choosing a dehumidifier to make sure it can handle your room size. How Much Do I Want To Spend? A key consideration when making this type of purchase is how much you're willing to spend. While the cost of the actual dehumidifier is the biggest concern, you should also consider the cost of running the machine. Some energy-efficient models boast a higher energy efficiency rating than standard dehumidifiers, but they are most likely a little more expensive upfront. If cost isn't as much of a concern, you could also consider a whole-house dehumidifier that is installed with your HVAC system. How Many People Live in The Home? Choosing a dehumidifier is not only about the size of the home, but also the capacity of the home. A house with just one person will tend to be less humid than a home with a family of six since fewer people are sweating, breathing, and heating the space. Larger families may need a larger size dehumidifier than an individual or couple, since the average humidity will be higher. Features to Consider When Purchasing a Dehumidifier Before you make your purchase decision, there are a few things that you must consider. Dehumidifiers have many different features and characteristics that may make them the wrong choice for your unique circumstances. When shopping for dehumidifiers, make sure to consider all of the following features carefully to avoid bringing home a dehumidifier that isn't right for you. Type of Dehumidifier There are two types of dehumidifiers that you can consider for your home: desiccant and refrigerant. Compressor Dehumidifier/Refrigerant Dehumidifier This is the standard type of dehumidifier. This type of dehumidifier uses a compressor to draw in air from your space and pull it over the refrigerated coils to create condensation. These models are efficient and can handle high levels of humidity. One flaw of these dehumidifiers is their noise level. They average between 50 and 60 decibels when running. Compressor dehumidifiers are also best used in warmer climates. The coils could freeze if the room temperature is below about 65 degrees Fahrenheit. Desiccant Dehumidifier Desiccant dehumidifiers are the ideal choice if you're in a colder climate since they can be used at any temperature above freezing. They are also more energy efficient since they don't need to cool down the air. Instead, the air is pulled through the desiccant, which acts like a sponge to remove excess moisture from the air. These models are also much quieter to operate than a compressor-based model, so they can be used in work environments and bedrooms without disturbing anyone. However, desiccant dehumidifiers expel air that is roughly 10-15 degrees warmer than the ambient air temperature, so this may be an issue for some people who like to keep their home at a low temperature. These humidifiers can handle the same relative humidity levels as a compressor, but they can cost a bit more to run in warmer temperatures. These models are effectively used in areas like crawl spaces and basements that may be cooler, wetter spaces. Fan Settings Most dehumidifiers have a low speed and a high-speed setting that enable a bit of extra control over how the machine operates. A high setting can be used for quickly drying out the air in a space, while a low setting can keep the noise disturbance to a minimum while maintaining proper humidity levels. Some models will also have a middle setting, but not all do. Most dehumidifiers will also offer a fan-only setting, which can help encourage airflow without affecting moisture levels. Energy Efficiency Though dehumidifiers don't cost more than a few cents per hour to operate, choosing an Energy Star-rated model is the best for your budget and the environment because it works more efficiently and operates at a lower cost. An energy-efficient dehumidifier will more quickly achieve the desired level of dehumidification you need, stopping musty odours, water damage, and allergens in their tracks. Built-In Hygrometer/Humidistat A built-in humidistat is the most convenient feature available on a dehumidifier. Rather than set a speed setting and walk away, you can set a precise humidity level that the machine should maintain. Not only does this feature enable energy savings since the machine only runs when the humidity rises above your desired setting, but you also won't have to manually turn on or shut off the dehumidifier. Since dry air can also be bad for your health, this feature can be a lifesaver if you forget to turn off the dehumidifier. Basin Pint Capacity The pint capacity of your dehumidifier is a key factor to consider since your room size and characteristics will influence the moisture level of your air. If your room houses your washer and dryer, has multiple windows and doors, or your home is in a more humid climate, you'll need a dehumidifier that can handle more pints of water per hour since there is a larger amount of water in your air. If your machine doesn't have the right pint capacity, your air quality will suffer. Aside from the efficiency of the appliance, you should also consider the reservoir's capacity since this will control how often you'll need to empty the reservoir. Most models only need to be emptied once or twice a day, but a smaller tank will require more frequent emptying or a hose connection. Room Coverage People buying a dehumidifier do need to double-check that their room size is within the appliance's capacity. To purchase the right size dehumidifier for your space, you'll first need to calculate the room's square footage. The larger it is, the higher capacity your dehumidifier will need to have. The general rule is that a small dehumidifier collects less than 20 pints of moisture per day, medium dehumidifiers collect between 30 and 40 pints per day, and large dehumidifiers collect more than 40 pints per day. Drainage Type There are two choices you have when draining the water from your reservoir. The first is manually emptying the bin. This is usually a simple, quick process, but it can become tedious if you need to empty the tank two or more times per day, especially if you work full time or want to go away for a weekend and keep your home's humidity in check. Though some models only need to be emptied once a day if they aren't being used in rooms with excessively humid air, this is still a less convenient option. If you have a small dehumidifier capacity for dehumidifier water or have a large amount of moisture in your air, a drain hose is the way to go. A hose can drain directly into a floor drain and can handle any number of pints of moisture per hour or day that you need. If you don't have a floor drain, a dehumidifier with a pump can be used to send the water up to a higher-level drainage spot like a sink. Our Top Picks:
